Isoquinoline derivatives as MGAT2 inhibitors

US10065945B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Richard Berger · Princeton, US
• Timothy A. Blizzard · Middletown, US
• Brian T. Campbell · Souderton, US
• Helen Chen · Livingston, US
• John S. Debenham · Scotch Plains, US
• Sunita V. Dewnani · Secaucus, US
• Byron DuBois · New York, US
• Candido Gude · Staten Island, US
• Zack Zhiqiang Guo · Morganville, US
• Bart Harper · New York, US
• Zhiyong Hu · Livingston, US
• Songnian Lin · Sparta, US
• Ping Liu · Shanghai, CN
• Ming Wang · Montgomery, US
• Feroze Ujjainwalla · Hoboken, US
• Jiayi Xu · Marlboro, US
• Libo Xu · Bound Brook, US
• Rui Zhang · Plainsboro, US

Key dates

• Filing date: Jan 20, 2015
• Grant date: Sep 4, 2018
• Expiry date: Aug 6, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.